Pertussis: Topical issues of epidemiology, diagnosis, and prevention
Abstract
Despite widespread vaccination, pertussis remains an important cause of infant morbidity and mortality. About 16 million people are ill with this disease and approximately 195 thousand children die worldwide every year. However, only 5—10% of all pertussis cases are diagnosed and notified. In spite of wide immunization coverage, there is really a pertussis epidemic in many countries of the world now; moreover, vaccinated children constitute a high proportion of disease cases. Adolescents and adults are a major reservoir for cyclic outbreaks of pertussis; however, they are rarely diagnosed with the disease. The review gives scientists' opinion on the causes of this phenomenon and proposed measures to reduce morbidity in different age groups. The severe and complicated forms of pertussis and fatal outcomes occur in babies during the first months of life and therefore current vaccination strategies should be aimed at preventing the infection just in this age group of children.
About the Authors
I. V. Nikolaeva
Kazan State Medical University; N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
A. D. Tsaregorodtsev
Kazan State Medical University; N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
References
1. Centers for Disease Control and Prevention. Pertussis in other countries. 2013; http://www.cdc.gov/pertassis/countries.litml.
2. World Health Organization. SAGE Working Group on Pertussis Vaccines (established March 2013). Background paper. 2014; http://www.who.int/immunization/sage/meet-ings/2014/april/l_Pertussis_background_FINAL4_web.pdf
3. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18: 2: 326-382.
4. Winter K., GlaserC, Watt J. et al. Pertussis Epidemic — California, 2014. Morb Mortal Wkly Rep 2014; 63: 1129-1132.
5. Таточенко В.К. Коклюш — недоуправляемая инфекция. Вопр соврем педиат 2014; 13: 2: 78—82. (Tatochenko V.K. Whooping cough — the non operated infection. Vopr sovrem pediat2014;13:2:78-82.)
6. Liko J., Steve G., Robison B.S. et al. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 2013; 7: 368: 6:581-582.
7. Кудин А.П., Дралова В.В., Марукович В.В. и др. Применение ингаляционных глюкокортикоидов при лечении коклюша у детей. Мед журн 2013; 4: 125—128. (KudinA.P., Dralova V.V., Marukovich V.V. et al. Application of inhalation glucocorticoids at treatment of pertussis at children. Med zhurn2013; 4: 125-128.)
8. Cherry J.D. Why do pertussis vaccines fail? Pediatrics 2012; 129: 968-970.
9. Moot F.R. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol 2010; 10: 1:36-49.
10. Борисова О.Ю., Мазурова И.К., Ивашинникова Г.А. и др. Генетическая характеристика штаммов Bordetella pertussis, выделенных от больных коклюшем в России. Медицинский альманах 2012; 2: 30—34. (Borisova O.Yu., Mazurova I.К., Ivashinnikova G.A. et al. The genetic characteristic of the strains Bordetella pertussis, allocated from patients with whooping cough in Russia. Meditsinskij al'manakh2012; 2: 30-34.)
11. Guiso N. Bordetella pertussis and pertussis vaccines. Clin Infect Dis 2009; 49:10 :1565-1569.
12. Cherry J. D., Heininger U. Pertussis and other Bordetella infections. In: R.D. Feigin, J.D. Cherry, G.J. Demmler, S. Kaplan (eds.). Textbook of pediatric infectious diseases. 5th ed. TheW. B. Saunders Co, Philadelphia 2004; 1588-1608.
13. Лапий Ф.И? Актуальность эффективной защиты против коклюша. Здоровье ребенка 2010; 3: 84—86. (Lapij F.I. Relevance of effective protection against whooping cough. Zdorov'e rebenka 2010; 3: 84-86.)
14. Bisgard K.M., PascualF.B., Ehresmann K.R. etal. Infant pertussis: who was the source? Pediat Infect Dis J 2004; 23: 985-989.
15. Lobzin Y.V., Bakhareva N. V. Retrospective Study of the Clinical Epidemiological Characteristics of Pertussis in Infants Prior to Their First Vaccination in the Russian Federation. Infectious diseases and therapy 2015; 4: 1.
16. Locht С Molecular aspects of Bordetella pertussis pathogenesis. Int Microbiol 1999; 2: 3: 137-44.
17. Soares S., Rocha G., Pissarra S. et al. Impact of rapid leukode-pletion on the outcome of severe clinical pertussis in young infants. Pediatrics 2010; 126: 816-827.
18. Sawa M., Cohen M., Irazmta J.E. et al. Fulminant pertussis: a multi-center study with new insights into the clinico-pathological mechanisms. Pediat Pulmonol 2009; 44: 10: 970-980.
19. Paddock CD., Sanden G.N., Cherry J.D. et al. Pathology and Pathogenesis of Fatal Bordetella pertussis Infection in Infants. Clin Infect Dis 2008; 47: 3: 328-338.
20. Попова О.П., Петрова М.С., Федорова ИМ. и др. Клини-ко-иммунологические особенности сочетанного течения коклюша и респираторного микоплазмоза у детей. Инфекционные болезни 2012; 10: 2: 43—48. (Popova О.Р., Petrova M.S., Fedorova I.M. et al. Clinical and immunologi-cal features of the combined course of whooping cough and respiratory mycoplasmosis at children. Infektsionnye bolezni 2012; 10: 2: 43-48.)
21. Centers for Disease Control and Prevention. Pertussis (Whooping Cough), Clinicians, Clinical Complications. 2012; http:/www.cdc.gov/pertussis/clinical/features.html.
22. Bortolussi R., Miller В., Ledwith M., Halperin S. Clinical course of pertussis in immunized children. Pediat Infect Dis J 1995; 14: 870.
23. Сиземов А.П., Комелева Е.В. Коклюш: клиника, диагностика, лечение. Лечащий врач 2005; 7: 82—87. (Sizemov A.N., Komeleva E.V Whooping cough: clinic, diagnostics, treatment. Lechashhij vrach 2005; 7: 82-87.)
24. Marshall П., Clarke M., Rasiah K. et al. Predictors of disease severity in children hospitalized for pertussis during an epidemic. Pediat Infect Dis J 2015; 34: 4: 339-345.
25. Centers for Disease Control and Prevention. Pertussis—United States, 1997—2000. Age distribution and incidence of reported cases. 2002; http: //www.cdc.gov/nip/ed/slides/per-tussis8p.pp
26. Kundraft S.L., Wolek T.L., Rowe-Telow M. Malignant pertussis in the pediatric intensive care unit. Dimens Crit Care Nurs 2010; 29: 1-5.
27. Rowlands HE., Goldman A.P., Harrington K. et al. Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 2010; 126: 816—827.
28. Theilen U., Johnston E.D., Robinson P.A. Rapidly fatal invasive pertussis in young infants—how can we change the outcome? BMJ 2008; 27: 337-343.
29. Surridge J., Segedin E.R., Grant C.C. Pertussis requiring intensive care. Arch Dis Child 2007; 92: 11: 970-975.
30. Versteegh E.G., Mooi-Kokenberg E.A., Schellekens J.F. et al. Bordetella pertussis and mixed infections. Minerva Pediat 2006; 58: 131.
31. Nuolivirta K., Koponen P., He Q. et al. Bordetella pertussis infection is common in nonvaccinated infants admitted for bronchiolitis. Pediat Infect Dis J 2010; 29: 1013.
32. ZouariA., TouatiA., Smaoui H. etal. Dual infection with Bordetella pertussis and Mycoplasma pneumoniae in three infants: case reports. Infection 2012; 40: 213.
33. СП 3.1.2.3162-14. Профилактика коклюша. Санитарно-эпидемиологические правила. 2014; http://35. rospotrebnadzor.ru/Default.aspx?et=4&ig (SP 3.1.2.3162-14. Prevention of whooping cough. Sanitary and epidemio-logic rules. 2014; http://35.rospotrebnadzor.ru/Default. aspx?et=4&ig)
34. Ценева Г.Я., Курова Н.Н. Микробиологическая характеристика возбудителя коклюша и лабораторная диагностика коклюша. Клин микробиол и антимикробная химиотер 2003; 4: 329—341. (Tseneva G.Ya., Kurova N.N. Microbiological characteristic of the causative agent of whooping cough and laboratory diagnosis of whooping cough. Klin mikrobiol i antimikrobnaya khi-mioter 2003; 4: 329-341.)
35. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women — Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2013; 62: 7: 131-135.
36. Zepp F., Heininger U., Mertsola J. et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011; 11: 7: 557–570.
37. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep 2011; 60: 13–15.
38. Terranella A., Asay G.R., Messonnier M.L. et al. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics 2013; 131: 5: 1748–1756.
39. Kharbanda E.O., Vazquez-Benitez G., Lipkind H.S. et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA 2014; 312: 18: 1897–1904.
40. Fedele G., Bianco M., Debrie A.S. et al. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J Immunol 2011; 186: 5388–5396.
41. Jahnmatz M., Amu S., Ljungman M. et al. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial. Vaccine 2014; 32: 3350.
42. Cherry J.D. Pertussis: Challenges Today and for the Future. PLoS Pathog 2013; 9: 7: 1003418.
Review
For citations:
Nikolaeva I.V., Tsaregorodtsev A.D. Pertussis: Topical issues of epidemiology, diagnosis, and prevention. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2015;60(5):162-167. (In Russ.)
Views:
1698
Email this article 